Krystexxa: Big Expectations For An Orphan Market
Executive Summary
Savient's Krystexxa, an orphan drug candidate for treatment-failure gout, could bring in $600 million or more in worldwide sales by 2015, considerably bumping up the firm's potential value and making it pretty enough for picking as a potential acquisition candidate - or at the very least a collaboration partner
You may also be interested in...
Savient On Track To Resubmit Krystexxa BLA In Early 2010, Exec Maintains
After a Sept. 14 meeting with the FDA, the biotech is confident it can satisfy all points in a complete response letter - including the gout therapy's REMS.
Savient's Gout Therapy Krystexxa Delayed At FDA.
Manufacturing fixes should be straightforward - but the REMS submission could be tricky.
Savient's Gout Therapy Krystexxa Delayed At FDA
The biggest delay in Savient's resubmission of its gout therapy Krystexxa (pegloticase) could come from FDA's request that the sponsor include detailed materials for its Risk Evaluation and Mitigation Strategy as part of the resubmission